← Eichor
Study identifier: NCT06727292 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Biometrical Evaluation of the Efficacy of a Food Supplement Versus Placebo

Condition: Skin Aging · Hair Condition · Skin Condition  ·  Sponsor: Finzelberg GmbH & Co. KG

PhaseNA
Planned participants66
Who can joinFemale, 45 Years to 65 Years
Healthy volunteersYes

About this study

The purpose of this clinical trial is to evaluate whether nutritional supplementation over a 2-month period improves skin physiological parameters. This is a national, single-center, double-blind, randomized pilot study. The study will be conducted using a supplement and a placebo, the safety of which has been assured by the sponsor. Participants will: * Take a food supplement or a placebo once daily for 2 months * Visit the study center at beginning, after 28 days and after 56 days of supplementation. * Keep a diary of their skin status and tolerability The secondary objective is to evaluate product characteristics and performance during normal use in healthy subjects.

This description comes directly from the study's public registry record.

Talk to the study team

Cynthia G Suarez, PhD  ·  004916098144462  ·  cynthia.suarez-rizzo@finzelberg.com

Always discuss trial participation with your own doctor first.

Locations (1)

Eurofins Dermscan PolandGdansk, GDANSK, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06727292